SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MG
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MG
SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MG is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Gout. The current trial status is completed. This product is registered under clinical trial identifier NCT04052932. Target conditions include Gout.
What happened to similar drugs?
7 of 20 similar drugs in Gout were approved
Approved (7) Terminated (3) Active (11)
🔄HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
🔄HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04052932 | Phase 3 | Completed |
Competing Products
20 competing products in Gout